RHA 2, RHA 3, RHA 4
FDA premarket approval P170002/S006 · decided 2020-01-30
Approval details
- PMA number
- P170002
- Supplement
- S006
- Supplement type
- 135 Review Track For 30-Day Notice
- Supplement reason
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
- Trade name
- RHA 2, RHA 3, RHA 4
- Generic name
- Implant, dermal, for aesthetic use
- Applicant
- Teoxane S.A.
- Date received
- 2019-06-28
- Decision date
- 2020-01-30
- Days to decision
- 216 days
- Decision code
- APPR
- Product code
- LMH
- Advisory committee
- General, Plastic Surgery
- Expedited review
- No
- Location
- Geneva
- Statement
- Approval for a transfer of the lidocaine assay and 2,6-DMA limit test from a contract laboratory to an in-house laboratory.
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.